Company Overview and News

0
KSB Pumps Limited - Appointment

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500249 KSBPUMPS

0
KSB Pumps Limited - Amalgamation/Merger

2018-04-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500249 KSBPUMPS

0
KSB Pumps Limited - Shareholders meeting

2018-04-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500249 KSBPUMPS

34
Market Live: Sensex dips over 150 pts, Nifty breaks 10,550; rupee falls to 66.80/$, Europe down

2018-04-25 moneycontrol
2:40 pm Rupee Update: The Indian rupee extended fall to 66.80 against the US dollar, down 42 paise from previous closing of 66.38 a dollar on bouts of month-end dollar demand from importers amid crude price volatility and rising US bond yields.
500249 JIPKY ICLQY 511389 532832 533179 532960 5225 534816 UCLQY 509220 SBAZ GICHSGFIN ATFL SYNGENE 500215 VOD 532508 539268 STRTECH 511676 532822 ULTRACEMCO SRLRY 500182 FORTIS 500180 KSBPUMPS Q0F PTL IBREALEST BHRYY 512573 532538 BHRQY VIDEOIND IDBLZ 532187 INFRATEL HDFCBANK HEROMOTOCO JSL BHARTIARTL IHHHF AVANTI VOD INDUSINDBK IBVENTURES IBN UCLQF JPASSOCIAT 532843 532532 532454 ICICIBANK 532374 VODPF HDB 532174 IDEA HRTQY PERSISTENT

0
KSB Pumps Limited - Financial Result Updates

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500249 KSBPUMPS

19
Market Live: Sensex remains weak, but IT stocks extend gain after rupee falls to 66.74/$

2018-04-25 moneycontrol
1:02 pm Economic Growth: Indian economy is expected to witness a cyclical recovery driven by investments as well as consumption, and the average GDP growth is expected to rise to 7.8 percent in the first half of this year, says a report.
BHRYY 500249 JIPKY 512573 532538 ICLQY BHRQY 532832 511389 VIDEOIND IDBLZ 532960 5225 534816 UCLQY 509220 HEROMOTOCO JSL INFRATEL BHARTIARTL IHHHF SBAZ ATFL SYNGENE 500215 VOD VOD AVANTI IBVENTURES 532508 539268 JPASSOCIAT UCLQF 532822 532843 ULTRACEMCO 532532 500182 532454 VODPF FORTIS IDEA HRTQY KSBPUMPS Q0F PTL IBREALEST

19
Market Live: Nifty below 10,600 amid consolidation; Wipro gains ahead of earnings

2018-04-25 moneycontrol
11:55 am Merger Approval: Bhageria Industries informed BSE that the National Company Law Tribunal [NCLT), Mumbai has approved the scheme of Amalgamation of Nipur Chemicals Limited with the company.
BHRYY 500249 JIPKY 512573 532538 ICLQY BHRQY 532832 IDBLZ 532960 5225 534816 UCLQY 509220 HEROMOTOCO JSL INFRATEL BHARTIARTL IHHHF SBAZ ATFL SYNGENE 500215 VOD VOD AVANTI IBVENTURES 532508 539268 JPASSOCIAT UCLQF 532822 532843 ULTRACEMCO 532532 500182 532454 VODPF FORTIS IDEA HRTQY KSBPUMPS Q0F PTL IBREALEST

1
Eyes on Wipro, UltraTech results

2018-04-24 thehindubusinessline
Index heavyweights Wipro and UltraTech Cement are among the dozen companies that will declare their quarter and full-year results for the period ended March 2018 on Wednesday. Others include Agro Tech Foods, Bajaj Corp, Future Supply Chain, GHCL, ICICI Lombard General Insurance, Indiabulls Real Estate, Jindal Stainless, KSB Pumps, M&M Financial Services, Reliance Nippon Life Asset Management, Sterlite Tech, Syngene International, Soril Holdings and Wendt (I).
ATFL SYNGENE 500215 500249 532508 539268 532538 UCLQF 532832 ULTRACEMCO UCLQY JSL KSBPUMPS IBREALEST

0
KSB Pumps Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500249 KSBPUMPS

0
KSB Pumps Limited - Press Release

2018-04-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500249 KSBPUMPS

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...